CYP2C19 and Stroke: Similarly, in cerebrovascular disease, the PRINCE trial (Table 2) showed that patients with minor stroke or TIA treated with ticagrelor plus aspirin exhibit reduced platelet reactivity compared to those receiving clopidogrel plus aspirin, especially so in carriers of the CYP2C19 LOF allele.53